Acyl hydrazines as kinase inhibitors, in particular for SGK

US7767716B2 · kind B2 · utility

Assignee

• Merck Patent GmbH · DE

Inventors

• Rolf Gericke · Seeheim-Jugenheim, DE
• Dieter Dorsch · Ober-Ramstadt, DE
• Werner Mederski · Zwingenberg, DE
• Markus Klein · Weiterstadt, DE
• Norbert Beier · Reinheim, DE
• Florian Lang · Gilching, DE

Key dates

• Filing date: Mar 10, 2006
• Grant date: Aug 3, 2010
• Expiry date: Sep 28, 2026

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07C255/57
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Novel acyl hydrazides of the formula (I), in which R1-R9 have the meanings indicated in claim 1, are SGK inhibitors and can be used for the treatment of SGK-induced diseases and complaints, such as diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases and renal diseases, generally in fibroses and inflammatory processes of any type.